• Korean
  • Chinese
年間契約型情報サービス - 104168

ラテンアメリカにおける医薬品業界見通し

The Outlook for Pharmaceuticals in Latin America

発行 Espicom Business Intelligence
出版日 年 4回更新 ページ情報 英文 8 separate reports
価格
ラテンアメリカにおける医薬品業界見通し The Outlook for Pharmaceuticals in Latin America
出版日: 年 4回更新 ページ情報: 英文 8 separate reports
概要

ラテンアメリカではブラジルを中心に著しい成長を遂げてきましたが、今後は鈍化すると見込まれています。しかし医療へのアクセスは富裕層以外にも広がっており、政府は費用抑制のため薬剤購入の集中管理を進めています。

当サービスでは、ラテンアメリカ各国の医薬品市場動向や規制、政策、経済発展動向、今後5年間の予測などをまとめ、概略下記の構成でお届けいたします。

網羅される国

  • アルゼンチン
  • ブラジル
  • チリ
  • コロンビア
  • キューバ
  • メキシコ
  • ペルー
  • ベネズエラ

市場見通し

  • 四半期最新動向
  • 国別データ予測

医薬品市場分析

  • 現在の市場規模
  • 市場構造
  • 5ヵ年予測
  • 輸入
  • 国内製造
  • 輸出
  • 研究開発

医薬品関連規制分析

  • 規制
  • 薬価
  • 償還
  • 知的財産

医薬品販売

医療分析

  • 人口統計
  • 医療制度
  • 医療費
  • 医療インフラと要員

医療関連データ

  • 年間データ
目次

Abstract

Summary

Strong pharmaceutical market growth opportunities and regulatory developments are making Latin America more attractive

Description

Strong pharmaceutical market growth opportunities and regulatory developments are making Latin America more attractive

The region needs to increase drug access, in spite of intensifying cost-containment measures. Therefore, attractive opportunities for (bio)pharmaceutical producers exist in Latin America. Brazil has the largest pharmaceutical market. Strong economic performance will fuel pharmacy sales growth in the forecast period. Mexico is the second leading market. Recent regulatory developments will create further market opportunities in the country, particularly for generic producers in both the private and public sectors. In Argentina, the pharmaceutical industry is expected to perform well in the coming years, with strong growth in production, sales, exports and employment. Pharmaceutical companies, however, are encouraged to act in smaller Latin American markets to maximise their full regional sales potential.

Generics consumption in Latin America is low, with the exception of Brazil which has a dynamic bioequivalent generic sector. In the last two years, foreign producers have penetrated what, until then, had been considered a tough sector due to local protectionism and low prices. Major developments include Pfizer's purchase of 40.0% of Teuto in November 2010, Valeant's acquisitions of two generic producers in the first half of 2010, and Sanofi's acquisition of the largest local generic company Medley in 2009. As a result, multinationals represented over 40.0% of the generic sector in 2010, compared to 12.0% in 2008. This wave of acquisitions is a blow for the government, which aims to create a leading local pharmaceutical group able to compete internationally.

In Mexico, the number of people accessing public healthcare will increase as the country is implementing universal health coverage, which means that some private pharmacy consumption will be transferred to the increasingly attractive public sector. Growth in the private pharmacy sector, therefore, is expected to be more moderate in the forecast period. Fuelled by the current economic slowdown and new regulatory measures, generics penetration in the pharmacy sector will increase and contain the private pharmacy sector by value. Strategically, Sanofi already acquired the local generic producer Kendrick in 2009, whilst Valeant acquired Tecnofarma. The amount of opportunities will be squeezed but the pharmaceutical market is large enough to be attractive in the long-term.

THESE REPORTS ANALYSE THE ISSUES

The Outlook for Pharmaceuticals in Latin America is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series.

HIGHLIGHTS FROM THE REGION...

ARGENTINA

There are over 200 pharmaceutical companies operating in the pharmacy sector, of which over half are Argentine. Local producers dominate the pharmacy sector, led by Roemmers, Bago, Gador and Elea. Recent significant developments include the agreement to start the construction of the Polo Farmaceutico de Buenos Aires, signed by 13 local companies in October 2011; Roemmers' acquisition of 50.0% of a small local OTC company, reported in July 2011; and Roemmers' two-year agreement to distribute and sell 26 primary care products from a Swiss company, announced in January 2011. Mexico and Brazil offer more incentives for multinationals to set up their regional subsidiaries, but two foreign companies made recent strategic acquisitions in the Argentine oncology market in QIII 2011. Previously, GSK acquired Laboratorios Phoenix in June 2010.

BRAZIL

The Brazilian pharmaceutical market ranks first in the Latin American region. Pharmaceutical demand will continue to rise, fuelled by increasing disposable income, therefore the market outlook is positive for the 2011-2016 period. Generics are expected to have a pharmacy market share of 20.0% by value and 25.0% by volume in 2011. Competition among the five leading pharmacy chains is fierce, and the sector has been consolidated by a recent wave of mergers. In September 2011, Drogaria Sao Paulo, the leader in the state of Sao Paulo, and Drogarias Pacheco, the leader in Rio de Janeiro, announced a merger, creating what will be the largest pharmacy chain in Brazil, DPSP. This merger took place after the merger between Drogasil and Droga Raia, announced in August 2011, creating the second largest pharmacy chain, Raia Drogasil.

CHILE

The Chilean pharmaceutical market is expected to increase by a moderate CAGR in US dollar terms between 2011 and 2016. In July 2011, the Institute of Public Health in Chile (ISPCH - Instituto de Salud Publica de Chile) confirmed that it had sent the project to create a National Medicines Agency (ANAMED - Agencia Nacional de Medicamentos) to the Congress. The new agency is expected to update the regulation of medicines, strengthen ISPCH's regulatory functions and implement a number of measures to increase the competitiveness of the pharmaceutical industry. The creation of ANAMED is part of President Sebastian Pinera's National Policy of Medicaments that aims to ensure that medicaments sold in Chile meet efficacy, safety and equivalence standards. The industry believes that the creation of ANAMED could speed up the pharmaceutical registration process.

COLOMBIA

The pharmaceutical market in Colombia is the fourth smallest pharmaceutical market in the Latin American region. The market is set to expand at a one-digit CAGR in dollar terms between 2011 and 2016. The economic and political environment is stable, therefore the outlook is positive for pharmaceutical market growth. Colombia is looking to increase drug access for the whole population under the universal insurance programme (SGSSS), which should expand the market accordingly. Pharmaceutical imports and exports will increase. The number of pharmaceutical companies operating in the market has also risen. Gross pharmaceutical production will continue its upward trend and the industry is expected to create more employment. The leading pharmaceutical company is Tecnoquimicas, followed by Baxter, Roche, Abbott and Bayer. In February 2011, Nycomed, now acquired by Takeda, announced the acquisition of a local company.

CUBA

The economy is expected to do well in the 2011-2016 period, and the Economist Intelligence Unit (EIU) believes that mid-term economic policy is expected to be focused on making the economic system more flexible and promoting more private initiatives. The Cuban pharmaceutical market is the smallest in the Latin American region but, based on current research, production and trade trends, Espicom projects a moderate CAGR in dollar terms between 2011 and 2016. The Cuban pharmaceutical market increased in value by five times in the 2075-2010 period. Cuba has developed a well-established pharmaceutical industry based on the formulation or manufacturing of generic medicines. An important Cuban biotechnology industry has also been developed. The government is responsible for domestic production, which represents between 80% and 90% of the market.

MEXICO

Generic sales in Mexico are still negligible in the private pharmacy sector. However, the National Association of Interchangeable Generic Medicines (AMEGI) believes that consumption of generic medicines in the private pharmacy sector will increase considerably in the forecast period. A number of patents for bestselling drugs will expire in the coming years, and this will accelerate generic market growth. Generic sales are high, when considering sales in the public sector. The public sector is accountable for about 80.0% of generic sales by value, whilst the private pharmacy sector represents the remaining 20.0%; generic sales represented 3.5% of pharmacy sales. In terms of competition, a number of foreign producers, i.e. Sanofi and Valeant, have acquired a couple of local producers, whilst others have formed partnerships with local producers.

PERU

The Peruvian pharmaceutical market is the second smallest in the region. The market is expected to increase by a moderate CAGR in dollar terms between 2011 and 2016. Pharmaceutical expenditure per capita is the lowest in the region. This means that there are growth opportunities, as the economy is expected to perform well in the forecast period. The market increased five times between 2075 and 2010. In January 2011, the Israeli company Teva Pharmaceutical Industries announced that it was acquiring Infarmasa from The Rohatyn Group (TRG) and Altra Investments. Teva commented that the combination of Medco, which is Teva's existing operation in Peru, and Infarmasa would create one of the top two pharmaceutical companies in the country.

VENEZUELA

Inflation rates are expected to remain extremely high in the forecast period, over-inflating the Venezuelan pharmaceutical market in local terms. GDP growth, particularly from 2012 onwards, and population growth are expected to encourage pharmaceutical sales, in spite of drug price controls and currency exchange controls. MPPS will continue to implement Barrio Adentro, but threats in the public sector include government drug imports from countries that co-operate with Venezuela and government pharmaceutical production. Espicom projects the Venezuelan market to rank as the fourth largest in the Latin American region in 2016. OTC and generic sales are expected to increase in the forecast period. There are about 33 pharmaceutical producers, most of which are local. Foreign producers have consolidated their regional operations in other countries in the last ten years, but Bayer, Daiichi Sankyo, Pfizer, Sanofi, La Sante and Teva remain.

Table of Contents

Argentina

Executive Summary 7

SWOT Analysis 9

  • Argentina Pharmaceuticals And Healthcare Industry SWOT 9
  • Argentina Political SWOT 10
  • Argentina Economic SWOT 10
  • Argentina Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12

  • Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12
  • Rewards 13
  • Risks 13

Argentina - Market Summary 15

Regulatory Regime 16

  • Table: Product Registration, Annex I & II Listed Countries 18
  • Biological Market Regulation 22
  • Generic Regulation 24
  • OTC Regulation 25
  • Intellectual Property Rights 26
  • Intellectual Property Environment 27
  • IP Disputes 29
  • Counterfeit Pharmaceuticals 31
  • Pricing & Reimbursement 32
  • Table: Major Measures 35
  • Table: Taxes Paid by the Pharmaceutical Industry by Type, 2005-2007 (ARSmn) 35
  • Pricing Regime 36
  • Table: Pharmaceutical Price Build-Up 36
  • Table: Drug Price Freeze, 2005-2008 37
  • Reimbursement Regime 38
  • Other Regulatory Issues 38

Industry Trends And Developments 40

  • Epidemiology 40
  • Healthcare System 41
  • Healthcare Insurance 42
  • Medical Tourism 43
  • Medicinal Plants 43
  • Research & Development 43
  • Pharmaceutical R&D Investment, 2001-07 44
  • Clinical Trials 45
  • Medical Devices 47

Industry Forecast Scenario 49

  • Overall Market Forecast 49
  • Table: Argentina Pharmaceutical Sales, Historical Data and Forecasts 50
  • Key Growth Factors - Industry 51
  • Table: Argentina Healthcare Expenditure Trends, Historical Data and Forecasts 52
  • Table: Argentina Government Healthcare Expenditure Trends, Historical Data and Forecasts 52
  • Table: Argentina Private Healthcare Expenditure Trends, Historical Data and Forecasts 53
  • Key Growth Factors - Macroeconomic 54
  • Prescription Drug Market Forecast 60
  • Table: Argentina Prescription Drug Market Indicators, Historical Data and Forecasts 61
  • Patented Drug Market Forecast 62
  • Table: Argentina Patented Drug Market Indicators, Historical Data and Forecasts 63
  • Generic Drug Market Forecast 64
  • Table: Argentina Generics Drug Market Indicators, Historical Data and Forecasts 65
  • OTC Medicine Market Forecast 66
  • Table: Argentina Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 67
  • Pharmaceutical Trade Forecast 68
  • Table: Argentina Pharmaceutical Trade Data And Forecasts (US$mn) 69
  • Table: Argentina Pharmaceutical Trade Data And Forecasts (ARSmn) 70
  • Medical Device Market Forecast 71
  • Table: Argentina Medical Device Market Indicators, Historical Data and Forecasts 71
  • Other Healthcare Forecasts 73
  • Key Risks To BMI's Forecast Scenario 73

Competitive Landscape 75

  • Pharmaceutical Industry 75
  • Domestic Pharmaceutical Sector 76
  • Table: Members of CAPDROFAR, 2012 79
  • Table: Members of CAPGEN, 2012 80
  • Table: Members of CILFA, 2012 81
  • Table: Members of COOPERALA, 2012 82
  • Foreign Pharmaceutical Sector 84
  • Table: Members of CAEMe, 2012 86
  • Table: Members of CAEMe, 2012 88
  • Table: Members of CAPEMVeL, 2012 89
  • Recent Company Developments 90
  • Vaccines Sector 100
  • Pharmaceutical Wholesale Sector 102
  • Table: Members of ADEM, 2012 103
  • Retail Pharmacy Sector 106

Company Profiles 112

  • Local Companies 112
    • Roemmers 112
    • Laboratorios Bagó 115
  • Multinational Companies 118
    • Pfizer 118
    • Roche 120
    • Novartis 122
    • GlaxoSmithKline 124
    • Sanofi 126
    • Merck & Co 128
    • Boehringer Ingelheim 130

Demographic Outlook 132

  • Table: Population By Age Group, 1990-2020 ('000) 133
  • Table: Population By Age Group, 1990-2020 (% of total) 133
  • Table: Key Population Ratios, 1990-2020 134
  • Table: Rural And Urban Population, 1990-2020 135

Glossary 136

BMI Methodology 138

  • How We Generate Our Pharmaceutical Industry Forecasts 138
  • Pharmaceutical Risk/Reward Ratings Methodology 139
  • Ratings Overview 139
  • Table: Pharmaceutical Risk/Reward Indicators 140
  • Weighting 141
  • Table: Weighting Of Components 141
  • Sources 141

Brazil

Executive Summary 7

SWOT Analysis 10

  • Brazil Pharmaceuticals And Healthcare Industry SWOT 10
  • Brazil Political SWOT 11
  • Brazil Economic SWOT 12
  • Brazil Business Environment SWOT 13

Pharmaceutical Risk/Reward Ratings 14

  • Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 14

Brazil - Market Summary 16

Regulatory Regime 18

  • Intellectual Property Environment 25
  • Counterfeits 28
  • Compulsory Licensing 29
  • Pricing Regime 30
  • Reimbursement Regime 34
  • Table: Medicines In The Partnership Deals 36
  • OTC Regulations 39
  • Advertising 41

Industry Developments 43

  • Epidemiology 43
  • Healthcare Sector 45
  • Healthcare Sector Funding 47
  • Research And Development 48
  • Biotechnology 51
  • Clinical Trials 58
  • Medical Devices Market 58
  • Medical Device Industry - Recent Developments 60
  • Medical Device Distribution 60

Industry Forecast Scenario 61

  • Overall Market Forecast 61
  • Table: Brazil Pharmaceutical Sales, Historical Data And Forecasts 62
  • Key Growth Factors - Industry 63
  • Table: Brazil Healthcare Expenditure Trends, Historical Data And Forecasts 65
  • Table: Brazil Government Healthcare Expenditure Trends, Historical Data And Forecasts 65
  • Table: Brazil Private Healthcare Expenditure Trends, Historical Data And Forecasts 66
  • Key Growth Factors - Macroeconomic 67
  • Table: Brazil - Economic Activity 72
  • Prescription Drug Market Forecast 73
  • Table: Brazil Prescription Drug Market Indicators, Historical Data And Forecasts 74
  • Patented Drug Market Forecast 75
  • Table: Brazil Patented Drug Market Indicators, Historical Data And Forecasts 76
  • Generic Drug Market Forecast 77
  • Table: Brazil Generics Drug Market Indicators, Historical Data And Forecasts 80
  • Table: Cumulative Active Ingredients, Registrations & Presentations Of Generics, 2000-April 2012 81
  • Table: Top-12 Leading Brands Losing Patent, 2012 82
  • OTC Medicine Market Forecast 84
  • Table: Brazil Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts 85
  • Pharmaceutical Trade Forecast 86
  • Table: Brazil Pharmaceutical Trade Data And Forecasts (US$mn) 88
  • Table: Brazil Pharmaceutical Trade Data And Forecasts (BRLmn) 89
  • Medical Device Market Forecast 90
  • Table: Brazil Medical Device Market Indicators, Historical Data And Forecasts 91
  • Other Healthcare Data 92
  • Key Risks To BMI's Forecast Scenario 92

Competitive Landscape 93

  • Pharmaceutical Industry 93
  • Top 20 Pharmaceutical Companies In Brazil By Sales In 2010 93
  • Innovative Drugmakers 94
  • Innovative Drugmakers - Recent Developments 94
  • Table: Members of ABIMIP, 2011 96
  • Table: Members Of INTERFARMA, 2011 97
  • Generic Drugmakers 106
  • Table: Members Of ALANAC, 2011 108
  • Table: Members Of ALFOB, 2011 109
  • Members Of Pró-Genéricos, 2011 110
  • Hypermarcas' Major Acquisitions, 2005-11 122
  • Table: Hypermarcas' Net Sales By Division, 2009-10 (R$mn) 123
  • OTC Sector 127
  • Pharmaceutical Distribution Sector 127
  • Table: Members Of ABAFARMA, 2012 129
  • Members Of ABRADILAN, 2012 130
  • Profarma's Net & Gross Sales, 2005-11 (R$mn) 136
  • Table: Profarma's Distribution Centres By Location, 2012 137
  • Santa Cruz's Distribution Centres By 137
  • Pharmaceutical Retail Sector 138
  • Table: ABRAFARMA's Ranking Of Pharmacy Chains By Sales, 2010-11 142
  • Table: ABRAFARMA's Ranking Of Pharmacy Chains By Number Of Outlets, 2010-11 143
  • Table: ABRAFARMA's Financial Indicators, 2008-11 144
  • Table: Members Of ABRAFARMA, 2012 145
  • Table: Members Of ASSIFARMA, 2012 146
  • Table: Members Of FEBRAFAR By Region, 2012 146
  • Table: Pague Menos' Gross Sales, 2000-11 151
  • Table: RaiaDrogasil's Gross Sales, 2001-11 (R$mn) 153
  • Table: RaiaDrogasil's Number Of Pharmacies, 2001-12 154

Company Profiles 155

  • Aché/Biosintética 155
  • EMS Sigma 158
  • Eurofarma 160
  • Medley 162
  • Cristália 164
  • Sanofi 166
  • Pfizer 168
  • Merck & Co 171
  • Novartis 174
  • GlaxoSmithKline 177
  • Roche 180

Demographic Outlook 182

  • Table: Brazil's Population By Age Group, 1990-2020 ('000) 183
  • Table: Brazil's Population By Age Group, 1990-2020 (% of total) 184
  • Table: Brazil's Key Population Ratios, 1990-2020 185
  • Table: Brazil's Rural And Urban Population, 1990-2020 185

Glossary 186

BMI Methodology 188

  • How We Generate Our Pharmaceutical Industry Forecasts 188
  • Pharmaceuticals Business Environment Ratings 189
  • Risk/Reward Ratings Methodology 189
  • Ratings Overview 189
  • Table: Pharmaceutical Business Environment Indicators 190
  • Weighting 191
  • Table: Weighting Of Components 191
  • Sources 191

Chile

BMI Industry View 7

  • BMI Industry View7

SWOT9

  • SWOT 9

Industry Forecast 11

  • Pharmaceutical Market Forecast 11
  • Table: Table: Pharmaceutical Sales Indicators 2008-2016 12
  • Healthcare Market Forecast 13
  • Table: Table: Healthcare Expenditure Indicators 2009-2017 14
  • Table: Table: Healthcare Governmental Indicators 2009-201714
  • Table: Table: Healthcare Private Indicators 2009-2017 15
  • Economic Analysis15
  • Table: CHILE - ECONOMIC ACTIVITY20
  • Industry Forecast - Prescription 21
  • Table: Table: Prescription Drug Sales Indicators 2008-2016 22
  • Industry Forecast Patented Drug Market Forecast 22
  • Table: Table: Patented Drug Market Indicators 2008-2016 23
  • Generics Forecast23
  • Table: Table: Generic Drug Sales Indicators 2009-2017 25
  • Industry Forecast OTC 25
  • Table: Table: OTC Medicine Sales Indicators 2009-2017 27
  • Industry Forecast import/export 28
  • Table: Exports And Imports Indicators 2009-2017 30
  • Table: ASILFA's Members, 201030
  • Table: CANALAB's Members, 2008 31
  • Table: CIF's Members, 2010 32
  • Industry Forecast Medical Devices 33
  • Table: Medical Devices Sales Indicators 2009-2017 34
  • Industry Forecast other healthcare data 34
  • Industry Forecast35

Industry Risk Reward Ratings 37

  • Industry Risk Reward Ratings 37
  • Table: Table: Americas Pharmaceutical Risk/Reward Ratings, Q412 37

Market Overview 40

  • Market Overview40

Industry Trends And Developments42

  • Industry Trends And Developments 42
  • Epidemiology 42
  • Healthcare Sector44
  • Table: Isapres Beneficiaries, 1990-200945
  • Table: Beneficiaries by Isapre Type, 2009 46
  • Table: Major Structural Implementations, 2000-2010 48
  • Table: The Five-Law Reform Bill48
  • Table: Isapres' Solvency Bill 52
  • Healthcare Sector Developments 53
  • Table: Physicians by Specialty, 2000-2009 56
  • Healthcare Insurance 56
  • Research And Development 60
  • Medical Devices63

Regulatory Development 65

  • Regulatory Development 65
  • Table: CORFO's INNOVA Chile's Biotechnology Manufacturers, 200773
  • Table: Table: Latin American Regulations On Bioequivalence And GMP 74
  • Table: List of Therapeutically Equivalent Pharmaceuticals, 15th July 2010 75
  • Intellectual Property Issues 77
  • Trade Agreements81
  • Pricing Regime 83
  • Table: Table: Pharmaceutical Price Build-Up (%) 85
  • Reimbursement Regime 86

Competitive Landscape 88

  • Competitive Landscape 88
  • Pharmaceutical Sector 88
  • Domestic Industry88
  • Foreign Industry90
  • Pharmaceutical Distribution 91
  • Table: SOCOFAR's Sales, 2002-2008 (COPmn)92
  • Pharmaceutical Retail Sector 92
  • Table: Pharmacies by Leading Pharmacy Chain, 2003-2009 96
  • Table: Farmacias Ahumada's Sales in Chile, 2002-2008 (COPmn) 98
  • Table: Farmacias Cruz Verde's Sales, 2002-2008 (Million Pesos) 99
  • Table: Pharmacy Sales Value by Sector, 2007-2008 (US$mn) 100
  • Table: Pharmacy Sales Volume by Sector, 2007-2008 (Million Units)101
  • Table: Summary of Pharmaceutical Establishments & Workforce, 2000-2007102
  • Table: Pharmaceutical Establishments & Workforce by Company Size, 2000-2007 102
  • Table: Summary of Pharmaceutical Production, 2000-2007 (COPmn)103
  • Table: Summary of Pharmaceutical Production, 2000-2007 (US$mn)104
  • Table: Pharmaceutical Production by Establishment Size, 2000-2007 (Million Pesos) 104

Company Profile 106

  • Laboratorios Chile (LabChile) 106
  • Corporacion Farmaceutica Recalcine (CFR) 109
  • Laboratorios Andromaco 113
  • Pfizer 116
  • Novartis 118
  • Sanofi 120
  • GlaxoSmithKline122
  • Merck & Co 124
  • Other Company Developments 125
  • Table: Andromaco's Workforce by Subsidiary, 2009 128
  • Table: Andromaco's Sales, 2002-2009 (Million Pesos)129

Demographic Forecast 132

  • Demographic Forecast 132
  • Table: Chile's Population By Age Group, 1990-2020 ('000) 133
  • Table: Chile's Population By Age Group, 1990-2020 (% of total) 134
  • Table: Chile's Key Population Ratios, 1990-2020 135
  • Table: Chile's Rural And Urban Population, 1990-2020 135

Glossary 136

  • Glossary 136

Methodology 138

  • Methodology 138
  • Risk/Reward Ratings Methodology 138
  • Ratings Overview139
  • Table: Pharmaceutical Business Environment Indicators 139
  • Weighting 140
  • Table: Weighting Of Components 140
  • Sources 140

Colombia

Executive Summary 7

SWOT Analysis 9

  • Colombia Pharmaceutical And Healthcare Industry SWOT 9
  • Colombia Political SWOT 10
  • Colombia Economic SWOT 10
  • Colombia Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12

  • Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12
  • Rewards 13
  • Risks 13

Colombia - Market Overview 15

Regulatory Regime 16

  • Other Regulatory Issues 17
  • Recent Regulatory Developments 18
  • Pharmaceutical Advertising 18
  • Intellectual Property Regime 19
  • Intellectual Property Shortcomings 21
  • Counterfeit Pharmaceuticals 22
  • Health-Related Litigation 24
  • Free Trade Agreement With The US 24
  • Table: Colombia-US FTA Mechanisms Relevant To Intellectual Property 25
  • Pricing Regime 25
  • Table: New Drug Pricing Classification by Type, 2005 26
  • Recent Pricing Regime Developments 27
  • Reimbursement Regime 28
  • National Drug Policy 30

Industry Developments 31

  • Epidemiology 31
  • HIV/AIDS 32
  • Healthcare Sector 33
  • Healthcare Insurance 34
  • Private Health Insurance 37
  • Healthcare Insurance Funding 37
  • Emergency Healthcare Reform 38
  • Medical Tourism 39
  • Research and Development (R&D) 39
  • Table: Pharmaceutical Research and Science Centre (CECIF) Members, 2012 40
  • Clinical Trials 41
  • Medical Devices 42

Industry Forecast Scenario 44

  • Pharmaceutical Market Forecast 44
  • Table: Pharmaceutical Sales, 2008-2016 44
  • Healthcare Market Forecast 46
  • Table: Overall Healthcare Expenditure, 2008-2016 48
  • Table: Government Healthcare Expenditure, 2008-2016 48
  • Table: Private Healthcare Expenditure, 2008-2016 49
  • Key Growth Factors - Macroeconomic 50
  • Prescription Drug Market Forecast 52
  • Table: Prescription Drug Sales, 2008-2016 53
  • Patented Drug Market Forecast 54
  • Table: Patented Drug Sales, 2008-2016 55
  • Generic Drug Market Forecast 56
  • Table: Generic Drug Sales, 2008-2016 57
  • OTC Medicine Market Forecast 58
  • Table: OTC Medicine Sales, 2008-2016 59
  • Pharmaceutical Trade Forecast 61
  • Table: Pharmaceutical Trade, 2009-2016 63
  • Medical Device Market Forecast 64
  • Table: Medical Device Sales, 2008-2016 64
  • Other Healthcare Data Forecasts 66
  • Key Risks To BMI's Forecast Scenario 66

Competitive Landscape 67

  • Pharmaceutical Industry 67
  • Table: Pharmaceutical Producers, 2000-2009 68
  • Table: Pharmaceutical Production, 2000-2009 68
  • Table: Pharmaceutical Personnel, 2000-2009 69
  • Domestic Pharmaceutical Sector 69
  • Foreign Pharmaceutical Sector 70
  • Table: Members Of Asociacion De Laboratorios Farmaceuticos De Investigacion (AFIDRO), 2012 70
  • Table: Leading Pharmaceutical Companies By Revenues, 2011 (COPmn) 71
  • Table: Leading Pharmaceutical Importers/Wholesalers By Revenues, 2011 73
  • Table: INVIMA-Certified Pharmaceutical Manufacturing Establishments, October 15 2010 74
  • Pharmaceutical Company Developments 80
  • Pharmaceutical Wholesale 81
  • Pharmaceutical Retail 82
  • Table: Leading Pharmaceutical Retailers, 2009-2010 83

Company Profiles 86

  • Local Companies 86
    • Tecnoquimicas 86
    • Lafrancol 89
    • Laboratorios Genfar SA 92
    • Laboratorios Bussie 94
  • Multinational Companies 96
    • GlaxoSmithKline 96
    • Pfizer 98
    • Merck & Co 100
    • Sanofi 102
    • Novartis 104

Demographic Outlook 105

  • Table: Population By Age Group, 1990-2020 ('000) 105
  • Table: Population By Age Group, 1990-2020 (% of total) 106
  • Table: Key Population Ratios, 1990-2020 107
  • Table: Rural And Urban Population, 1990-2020 107

Glossary 108

BMI Methodology 110

  • How We Generate Our Pharmaceutical Industry Forecasts 110
  • Pharmaceutical Risk/Reward Ratings Methodology 111
  • Ratings Overview 111
  • Table: Pharmaceutical Risk/Reward Indicators 112
  • Weighting 113
  • Table: Weighting Of Components 113
  • Sources 113

Cuba

Mexico

Executive Summary 8

SWOT Analysis 10

  • Mexico Pharmaceuticals And Healthcare Industry SWOT 10
  • Mexico Political SWOT 11
  • Mexico Economic SWOT 11
  • Mexico Business Environment SWOT 12

Pharmaceutical Risk/Reward Ratings 13

  • Table: Americas Pharmaceutical And Healthcare Risk/Reward Ratings, Q113 13
  • Rewards 15
  • Risks 15

Mexico - Market Summary 17

Regulatory Regime 19

  • Marketing Registration 20
  • Table: Legal Pharmaceutical Registration Requirements 21
  • Table: Legal Pharmaceutical Registration Requirements 21
  • Import Regulation 22
  • Table: Import Fees 23
  • Table: Registration Renewal Requirements 23
  • Release Of Manufacturing Requirements 23
  • Regulation Of Antibiotics 24
  • Post-Marketing 24
  • Advertising 25
  • Biologics And Biosimilar Guideline 26
  • Research & Development 29
  • Table: NOM-177-SSA1-1998's Generic Tests 32
  • Intellectual Property Rights 32
  • Intellectual Property Environment 34
  • IP Shortcomings 35
  • Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights 36
  • Counterfeit Drugs 37
  • Pricing & Reimbursement 38
  • Reimbursement 40
  • Pricing Issues 41
  • Pricing Developments 43
  • Reimbursement Issues 44
  • Other Regulatory Developments 44

Industry Trends and Developments 46

  • Epidemiology 46
  • Non-Communicable Diseases 47
  • Healthcare Sector 47
  • Health Insurance 48
  • Healthcare Sector Funding 50
  • Medical Tourism 50
  • Research & Development 51
  • Clinical Trials 53
  • Table: Clinical Trial Regulation In Mexico 54
  • Table: Clinical Studies, 2003-09 56
  • Medical Devices 57

Industry Forecast Scenario 58

  • Overall Market Forecast 58
  • Table: Pharmaceutical Sales Indicators 2008-2016 59
  • Key Growth Drivers - Industry 60
  • Table: Healthcare Expenditure Indicators 2008-2016 61
  • Table: Healthcare Governmental Indicators 2008-2016 62
  • Table: Healthcare Private Indicators 2008-2016 62

Key Growth Drivers - Macroeconomic 64

  • Table: Mexico Macro Indicators 69
  • Prescription Drug Market Forecast 70
  • Table: Prescription Drug Sales Indicators 2008-2016 71
  • Patented Drug Market Forecast 72
  • Table: Patented Drug Market Indicators 2008-2016 73
  • Generic Drug Market Forecast 74
  • Table: Generic Drug Sales Indicators, 2008-2016 76
  • Associations 76
  • Table: Members of AMEGI, 2011 77
  • Members of ANAFAM, 2011 78
  • OTC Medicine Market Forecast 80
  • Table: OTC Medicine Sales Indicators 2008-2016 82
  • Pharmaceutical Trade Forecast 83
  • Table: Exports and Imports Indicators 2008-2016 84
  • Medical Device Market Forecast 86
  • Table: Medical Devices Sales Indicators, 2008-2016 86
  • Other Healthcare Data 87
  • Key Risks To BMI's Forecast Scenario 87

Competitive Landscape 89

  • Pharmaceuticals Industry 89
  • Pharmaceutical Company Activity 90
  • Foreign Competition 90
  • Table: Members of AFAMELA, 2012 90
  • Table: Members of AMIIF, 2012 91
  • Table: Members of CANIFARMA, 2012 93
  • Table: AstraZeneca's Sales, 2005-10 96
  • Pharmaceutical Distribution Sector 104
  • Wholesale 104
  • DIPROFAR 104
  • Grupo Casa Saba 104
  • Marzam 105
  • NADRO 106
  • Pharmaceuticals Retail Sector 107
  • Table: IMSS Pharmacies, 2000-11 107
  • Table: IMSS Financial Indicators, 2000-11 (MXNmn) 109
  • Table: Leading Pharmaceutical Suppliers to IMSS, 2010-12 (MXNmn) 110
  • Table: IMSS Expenditure on Disease & Maternity Insurance by State, 2011 (MXNmn) 110
  • ISSSTE 112
  • Table: ISSSTE's Pharmaceutical Expenditure, 2006-12 112
  • Seguro Popular 113
  • Table: SPSS Budget, 2004-11 (MXNmn) 114
  • Table: FPGC Disease Groups, 2011 115
  • Table: FPGC Cases & Cost By Disease, Authorised In 2011, Validated And Paid By December 31 2011 116
  • Associations of Independent Pharmacies 118
  • Table: Members of ANADIM, 2012 119
  • Members of ANEFAR, 2012 120
  • Pharmacy Chains 121
  • Farmacias del Ahorro 121
  • Farmacias Benavides 121
  • Table: Farmacias Benavides' Key Indicators, 2003-11 122
  • Farmacias El Fenix 122
  • Corporativo Fragua 123
  • Table: Corporativo Fragua's Key Indicators, 2005-11 123
  • Farmacias Similares 124
  • Walmart 125

Company Profiles 127

  • Local Company Profiles 127
    • Genomma Labs 127
  • Multinational Companies 131
    • Pfizer 131
    • GlaxoSmithKline (GSK) 133
    • Sanofi 135
    • Eli Lilly 138
    • Bristol-Myers Squibb 140
    • Novartis 142
    • Bayer 145
    • Boehringer Ingelheim 147
    • Merck KGaA 150
    • Roche Syntex 152

Demographic Outlook 155

  • Mexico - Population By Age Group 156
  • Mexico - Population By Age Group 157
  • Mexico - Key Population Ratios 158
  • Mexico - Rural and Urban Population 158

Glossary 159

BMI Methodology 161

  • How We Generate Our Pharmaceutical Industry Forecasts 161
  • Pharmaceutical Risk/Reward Ratings Methodology 162
  • Ratings Overview 162
  • Table: Pharmaceutical Risk/Reward Indicators 163
  • Weighting 164
  • Table: Weighting Of Components 164
  • Sources 164

Peru

Executive Summary 7

SWOT Analysis 9

  • Peru Pharmaceuticals And Healthcare Industry SWOT 9
  • Peru Political SWOT 10
  • Peru Economic SWOT 11
  • Peru Business Environment SWOT 11
  • Pharmaceutical Risk/Reward Ratings 12
  • Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12
  • Rewards 13
  • Risks 14

Peru - Market Summary 15

Regulatory Regime 16

  • Recent Regulatory Developments 17
  • Pharmaceutical Advertising 18
  • OTC Medicines 19
  • Phytotherapeutics 19
  • Regional Harmonisation 20
  • Intellectual Property Regime 20
  • IP Shortcomings 21
  • Counterfeit Pharmaceuticals 23
  • Trade Agreements 24
  • Pricing Regime 25
  • Table: Peruvian Watchdog of Pharmaceutical Products (Observatorio Peruano de Productos Farmacéuticos, OPPF) 26
  • Reimbursement Regime 26
  • Government Tenders 27
  • Table: Public Procurement of Pharmaceuticals by Provider, 2007-2009 (Million Soles) 28
  • Pricing And Reimbursement Developments 29

Industry Developments 32

  • Epidemiology 32
  • Table: Selected Causes of Death by Sex, 2010 32
  • Non-Communicable Diseases 35
  • Communicable Diseases 36
  • Healthcare Sector 38
  • Table: MINSA's Decentralised Institutions & Institutes, 2011 38
  • Healthcare Sector Developments 39
  • Healthcare Finances 41
  • Healthcare Provision 42
  • Table: Infrastructure, 2004-2009 42
  • Table: Key Goals of Parsalud II In Nine Regions 43
  • Health Insurance 43
  • Research and Development (R&D) 44
  • Clinical Trials 45
  • Medical Devices 46

Industry Forecast Scenario 48

  • Pharmaceutical Market Forecast 48
  • Table: Pharmaceutical Sales Indicators 2008-2016 50
  • Healthcare Market Forecast 51
  • Table: Healthcare Expenditure Indicators 2008-2016 52
  • Table: Healthcare Governmental Indicators 2008-2016 52
  • Table: Healthcare Private Indicators 2008-2016 53
  • Key Growth Factors - Macroeconomic 54
  • Table: Puru Macro Indicators 58
  • Prescription Drug Market Forecast 59
  • Table: Prescription Drug Sales Indicators 2008-2016 60
  • Patented Drug Market Forecast 61
  • Table: Patented Drug Market Indicators 2008-2016 62
  • Generic Drug Market Forecast 63
  • Table: Generic Drug Sales Indicators 2008-2016 66
  • OTC Medicine Market Forecast 67
  • Table: OTC Medicine Sales Indicators 2008-2016 68
  • Pharmaceutical Trade Forecast 69
  • Table: Exports and Imports Indicators 2008-2016 71
  • Medical Device Market Forecast 72
  • Table: Medical Devices Sales Indicators 2008-2016 73
  • Other Healthcare Data 74
  • Key Risks To BMI's Forecast Scenario 75

Competitive Landscape 76

  • Pharmaceutical Sector 76
  • Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006 76
  • Table Members of ADIFAN, 2011 77
  • Table: Members of ALAFARPE, 2011 78
  • Table: Members of COMSALUD, 2011 78
  • Foreign Industry 80
  • Domestic Industry 82
  • Table: Domestic Production, 1992-2009 82
  • Pharmaceutical Distribution 83
  • Pharmaceutical Retail 84

Company Profiles 88

  • Domestic Companies 88
    • Farmaindustria 88
    • Unimed 90
    • Hersil 91
  • Multinational Companies 93
    • Sanofi 93
    • Merck & Co 94
    • GlaxoSmithKline 95
    • Novartis 96
    • Pfizer 97
    • AstraZeneca 98
    • Teva (Corporación Medco) 99

Demographic Outlook 101

  • Table: Peru's Population By Age Group, 1990-2020 ('000) 102
  • Table: Peru's Population By Age Group, 1990-2020 (% of total) 103
  • Table: Peru's Key Population Ratios, 1990-2020 104
  • Table: Peru's Rural And Urban Population, 1990-2020 104

Glossary 105

BMI Methodology 107

  • How We Generate Our Pharmaceutical Industry Forecasts 107
  • Pharmaceuticals Business Environment Ratings 108
  • Risk/Reward Ratings Methodology 108
  • Ratings Overview 108
  • Table: Pharmaceutical Business Environment Indicators 109
  • Weighting 110
  • Table: Weighting Of Components 110
  • Sources 110

Venezuela

BMI Industry View 7

SWOT 9

  • Political 11
  • Economic 12
  • Business Environment 13

Industry Forecast 14

  • Pharmaceutical Market Forecast 14
  • Table: Pharmaceutical Sales, 2009-2017 15
  • Healthcare Market Forecast 16
  • Table: Overall Healthcare Expenditure, 2009-2017 17
  • Table: Government Healthcare Expenditure, 2009-2017 17
  • Table: Private Healthcare Expenditure, 2009-2017 18
  • Table: VENEZUELA - ECONOMIC ACTIVITY 24
  • Prescription Drug Market Forecast 24
  • Table: Prescription Drug Sales, 2009-2017 25
  • Patented Drug Market Forecast 26
  • Table: Patented Drug Sales, 2009-2017 27
  • Generic Drug Market Forecast 28
  • Table: Generic Drug Sales, 2009-2017 29
  • OTC Drug Market Forecast 30
  • Table: OTC Medicine Sales, 2009-2017 31
  • Industry Forecast Import/Export 32
  • Table: Pharmaceutical Trade, 2009-2017 34
  • Table: Pharmaceutical Trade, 2008-2016 34
  • Medical Devices Forecast 35
  • Table: Table: Medical Device Sales, 2009-2017 36
  • Industry Forecast Other Healthcare Data 36
  • Key Risks To BMI's Forecast Scenario 37

Industry Risk Reward Ratings 39

  • Table: Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 39

Market Overview 42

Industry Trends And Developments 43

  • Epidemiology 43
  • Communicable Diseases 43
  • Non-Communicable Diseases 44
  • Healthcare Sector Developments 46
  • Hospital Sector 51
  • Private Healthcare Sector 59
  • Supply Chain 63
  • Table: Members of CAVEDRO, 2009 64
  • Research & Development 66
  • Medical Devices 67
  • Regulatory Development 69
  • Regulatory Regime 69
  • Intellectual Property 70

Regulatory Developments 72

  • Pharmaceutical Registration 73
  • Table: Registration Requirements 74
  • Table: Renewal Requirements 76
  • Advertising 77
  • Biologics And Biosimilars 78
  • Intellectual Property Issues 78
  • International Collaboration 81
  • Pricing 82
  • Reimbursement 87

Competitive Landscape 88

  • Pharmaceutical Sector 88
  • Foreign Industry 89
  • Domestic Industry 91
  • Table: Members of CAMESIP, 2010 93
  • Pharmaceutical Distribution 93
  • Table: Members of CAVEFAR, 2009 95
  • Production 98
  • Table: Members of CAVEME, 2010 99
  • Table: Members of CIFAR, 2010 100
  • Company Developments 101

Company Profile 110

  • Grupo Farma 110
  • Elmor 113
  • Strides Latina (Sumifarma) 116
  • Calox International 118
  • Pfizer 120
  • Sanofi 124
  • GlaxoSmithKline 126
  • Boehringer Ingelheim 129
  • Novartis 131
  • Merck & Co 133

Demographic Forecast 135

  • Venezuela Demographic Data 135
  • Table: Venezuela's Population By Age Group, 1990-2020 ('000) 136
  • Table: Venezuela's Population By Age Group, 1990-2020 (% of total) 137
  • Table: Venezuela's Key Population Ratios, 1990-2020 138
  • Table: Venezuela's Rural And Urban Population, 1990-2020 138

Glossary 139

Methodology 141

  • Methodology 141
  • Risk/Reward Ratings Methodology 141
  • Ratings Overview 142
  • Table: Pharmaceutical Business Environment Indicators 142
  • Weighting 143
  • Table: Weighting Of Components 143
  • Sources 143
Back to Top